Adverse Events | Gefitinib | Erlotinib | Afatinib | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NEJSG002 | IPASS | First-SIGNAL | WJTOG3405 | OPTIMAL | EURTAC | LUX-LUNG 3 | ||||||||
Grade 1–4 | Grade >3 | Grade 1–4 | Grade >3 | Grade 1–4 | Grade >3 | Grade 1–4 | Grade >3 | Grade 1–4 | Grade >3 | Grade 1–4 | Grade >3 | Grade 1–4 | Grade >3 | |
Rash | 71 | 5 | 66 | 3 | 72 | 29 | 85 | 1 | 73 | 2 | 80 | 13 | 89 | 16 |
Diarrhea | 34 | 1 | 46 | 4 | 50 | 2 | 54 | 1 | 25 | 1 | 57 | 5 | 95 | 14 |
Fatigue | 10 | 2 | 17 | 1 | 28 | 10 | 39 | 1 | 5 | 0 | 57 | 6 | 17 | 1 |
Stomatitis | NA | NA | 17 | 1 | 40 | 2 | 22 | 0 | 13 | 1 | NA | NA | 70 | 9 |
Vomiting | NA | NA | 13 | 1 | 19 | 0 | NA | NA | 1 | 0 | NA | NA | 17 | 3 |
AST/ALT elevation | 54 | 26 | NA | NA | 30 | 11 | 70 | 27 | 37 | 4 | 6 | 2 | NA | NA |
Data are percentages.
ALT, alanine transaminase; AST, aspartate transaminase; NA, not available.